Old Web
English
Sign In
Acemap
>
authorDetail
>
Ransi Somaratne
Ransi Somaratne
Durham University
Internal medicine
Gastroenterology
Virology
FGF19
Placebo
3
Papers
64
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
2019
Journal of Hepatology
Gideon M. Hirschfield
Olivier Chazouillères
Joost P. H. Drenth
Douglas Thorburn
Stephen A. Harrison
Charles S. Landis
Marlyn J. Mayo
Andrew J. Muir
James F. Trotter
Diana Julie Leeming
Morten A. Karsdal
Mark J. Jaros
Lei Ling
Kathline H. Kim
Stephen J. Rossi
Ransi Somaratne
Alex M. DePaoli
Ulrich Beuers
Show All
Source
Cite
Save
Citations (62)
NGM282 Significantly Reduces Hepatic Steatosis Independent of Type 2 Diabetes (T2D) Status or Statin Usage—Results from a Phase 2 Trial in Patients with Nonalcoholic Steatohepatitis (NASH)
2018
Diabetes
Alex M. DePaoli
Stephen J. Rossi
Lei Ling
Stephen A. Harrison
Manal F. Abdelmalek
Mark Jaros
Ransi Somaratne
Show All
Source
Cite
Save
Citations (1)
NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: Results of a phase 2, multicenter, randomized, doubleblind, placebo-controlled trial
2018
Journal of Hepatology
Gideon M. Hirschfield
Olivier Chazouillères
J. Ph Drenth
Douglas Thorburn
Stephen A. Harrison
Charles S. Landis
Marlyn J. Mayo
Andrew J. Muir
James F. Trotter
Morten A. Karsdal
Mark J. Jaros
Lei Ling
Kathline H. Kim
Stephen J. Rossi
Ransi Somaratne
Alex M. DePaoli
U. Beuers
Show All
Source
Cite
Save
Citations (1)
1